EMS - Generic and Prescription Pharmaceuticals

The EMS Sigma Pharma Group is a multinational Brazilian pharmaceutical group, with a comprehensive portfolio of over 1,000 pharmaceutical products, including value-added prescription drug products and the largest line of generic drugs in Brazil. Germed, a European affiliate of EMS, markets generic and prescription pharmaceutical products in Portugal. EMS is EU GMP approved to export solid, semi-solid forms, soft-gel caps, liquids and creams to Europe.

GENERIC AND PRESCRIPTION PHARMACEUTICAL DRUGS

EMS produces liquid, solid, semi-solid, injectable and soft-gel caps. We have expertise across a wide range of prescription medicine, generics, hospital and OTC sectors and applications. The company's operating structure includes continual investment to constantly update pharmaceutical manufacturing technology, equipment and operating processes. Our highly-trained team of employees consists of more than 3,000 staff across industrial, administrative, commercial and technical areas.

CYCLOSPORINE IMMUNOSUPRESSANTS

The immunosuppressant market is one of the Group's key operational sectors. Our focus on maintaining state-of-the-art practices and targeting investment towards this sector has led to our manufacture of the only cyclosporine microemulsion plant in the Southern Hemisphere.

Cyclosporine is used to prevent the rejection of transplanted organs and our reputation as a manufacturer of high quality cyclosporine microemulsion is a source of pride to the whole Group, and a reference point for the national industry.

PHARMACOLOGY EXPERTISE AND TECHNOLOGY

Ongoing improvement in our pharmacology technology is critical to the Group's expansion. Production automation is already in place, and our pharmaceutical analysis processes (following GMP) ensure quality standards from raw material to final product. With a production capacity of 220 million units per year, the Group offers an extensive line of prescription and generic medication to domestic and international markets.

The group invests heavily in state-of-the-art pharmaceutical manufacturing and analysis equipment and professional training. Our Research and Development (R&D) area is recognized as a world class EU GLP compliant development center. The Group is supported by renowned national and international consultants, and in partnership with major universities. This not only enables the exchange of knowledge and experience but also enables high levels of productivity.

PIONEERING GENERICS PRODUCTION

EMS is the first laboratory to get approval from Anvisa (Brazil's national health vigilance agency) to produce generic drugs in Brazil. This approval is an acknowledgement of our reputation in the generics market and our investment in research, equipment and pharmacological expertise. Currently, the Group leads the field with the largest line of generics drugs in Brazil, across all the major therapeutic classes.

GENERIC AND PRESCRIPTION DRUGS FOR EU MARKETS

Germed, a European affiliate of EMS, markets generic and prescription pharmaceutical products in Portugal. EMS is EU GMP approved to export solid, semi-solid forms, soft-gel caps, liquids and creams to Europe. The Group owns generic products targeting more than €2billion in EU brands. All products are on CTD format and EU Bioequivalence compliant. EMS owns more than 100 generic products for non-ICH countries.